A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China

Exclusion Criteria

• •Patients who are pregnant or breast feeding at enrolment or wish to become pregnant during the following adalimumab treatment and within 150 days since adalimumab discontinuation;
• •Patients in any psoriasis related clinical trial at the time of enrolment, at baseline or at any point during the study follow-up;
• •Patients with active tuberculosis or other severe infections (e.g. sepsis and opportunistic infections) as well as moderate to severe cardiac insufficiency.
• •Patients with difficulties for adequately reading, understanding and completing patient questionnaires.